CYTEK BIOSCIENCES INC (CTKB) Stock Price & Overview

NASDAQ:CTKB • US23285D1090

Current stock price

4.655 USD
+0.03 (+0.54%)
Last:

The current stock price of CTKB is 4.655 USD. Today CTKB is up by 0.54%. In the past month the price decreased by -1.7%. In the past year, price increased by 22.81%.

CTKB Key Statistics

52-Week Range2.37 - 6.18
Current CTKB stock price positioned within its 52-week range.
1-Month Range4.19 - 4.85
Current CTKB stock price positioned within its 1-month range.
Market Cap
598.4M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.21
Dividend Yield
N/A

CTKB Stock Performance

Today
+0.54%
1 Week
+0.22%
1 Month
-1.70%
3 Months
-12.14%
Longer-term
6 Months +8.69%
1 Year +22.81%
2 Years -22.96%
3 Years -59.67%
5 Years N/A
10 Years N/A

CTKB Stock Chart

CYTEK BIOSCIENCES INC / CTKB Daily stock chart

CTKB Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to CTKB. When comparing the yearly performance of all stocks, CTKB turns out to be only a medium performer in the overall market: it outperformed 48.73% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CTKB Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CTKB. The financial health of CTKB is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CTKB Earnings

On February 26, 2026 CTKB reported an EPS of -0.04 and a revenue of 62.14M. The company missed EPS expectations (-96.08% surprise) and beat revenue expectations (6.53% surprise).

Next Earnings DateMay 13, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$0.04
Revenue Reported62.141M
EPS Surprise -96.08%
Revenue Surprise 6.53%

CTKB Forecast & Estimates

11 analysts have analysed CTKB and the average price target is 6.12 USD. This implies a price increase of 31.47% is expected in the next year compared to the current price of 4.655.

For the next year, analysts expect an EPS growth of 20.67% and a revenue growth 5.81% for CTKB


Analysts
Analysts78.18
Price Target6.12 (31.47%)
EPS Next Y20.67%
Revenue Next Year5.81%

CTKB Groups

Sector & Classification

CTKB Financial Highlights

Over the last trailing twelve months CTKB reported a non-GAAP Earnings per Share(EPS) of -0.21. The EPS decreased by -320% compared to the year before.


Income Statements
Revenue(TTM)201.49M
Net Income(TTM)-66.54M
Industry RankSector Rank
PM (TTM) N/A
ROA -14.42%
ROE -19.47%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-157.14%
Sales Q2Q%8.12%
EPS 1Y (TTM)-320%
Revenue 1Y (TTM)0.52%

CTKB Ownership

Ownership
Inst Owners64.66%
Shares128.55M
Float117.69M
Ins Owners8.4%
Short Float %6.85%
Short Ratio10.28

About CTKB

Company Profile

CTKB logo image Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 702 full-time employees. The company went IPO on 2021-07-23. The firm is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.

Company Info

IPO: 2021-07-23

CYTEK BIOSCIENCES INC

47215 Lakeview Boulevard

Fremont CALIFORNIA US

Employees: 702

CTKB Company Website

CTKB Investor Relations

Phone: 18779229835

CYTEK BIOSCIENCES INC / CTKB FAQ

What does CYTEK BIOSCIENCES INC do?

Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 702 full-time employees. The company went IPO on 2021-07-23. The firm is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.


What is the current price of CTKB stock?

The current stock price of CTKB is 4.655 USD. The price increased by 0.54% in the last trading session.


What is the dividend status of CYTEK BIOSCIENCES INC?

CTKB does not pay a dividend.


What is the ChartMill technical and fundamental rating of CTKB stock?

CTKB has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the PE ratio for CTKB stock?

CYTEK BIOSCIENCES INC (CTKB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.21).


Is CYTEK BIOSCIENCES INC (CTKB) expected to grow?

The Revenue of CYTEK BIOSCIENCES INC (CTKB) is expected to grow by 5.81% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


Can you provide the market cap for CYTEK BIOSCIENCES INC?

CYTEK BIOSCIENCES INC (CTKB) has a market capitalization of 598.40M USD. This makes CTKB a Small Cap stock.